ArticleFrontiers in immunology2026
Incident psoriasis in atopic dermatitis: a large-scale cohort study of disease- and treatment-associated risks.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clinical and genetic evidence on the association between atopic dermatitis (AD) and subsequent psoriasis remains conflicting, and it is unclear whether this risk is modified by systemic treatments. Recent reports suggest that type 2-targeted biologics may unmask psoriasis in patients with AD, but data are limited. We thus aimed to assess whether AD is associated with incident psoriasis and whether this risk differs by systemic treatment, particularly biologics versus conventional systemic immunosuppressants (cvIS). Methods: Scoping analyses informed a locked analytic design, preregistration at Open Science Framework, and confirmatory execution. Propensity score-matched analyses compared AD with non-AD controls and biologics with cvIS. Sensitivity analyses, including multivariable Cox proportional hazards (CPH) analyses, and control outcomes assessed robustness. Results: Among ~300,000 matched pairs, AD was associated with increased psoriasis risk [primary hazard ratio (HR) 3.81, 95% confidence interval (CI) 3.35-4.34], consistent across all eight sensitivity analyses and CPH. Biologic treatment was associated with reduced psoriasis risk versus cvIS (primary HR 0.20; 95% CI 0.11-0.35), consistent across eight of nine evaluable sensitivity analyses and CPH. Positive and negative control outcomes showed expected directional patterns. Conclusions: Acknowledging limitations including residual confounding and coding misclassification, AD was associated with increased psoriasis risk and biologics with lower psoriasis risk than cvIS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.